Lucas Wong is an Oncology physician affiliated with Baylor Scott & White Health. OpenAlex indexes 75 publications with 1,639 citations (h-index 16); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2401 S 31st St
Temple, TX 765080001
Telephone
254-724-2111Provider last certified this registry record 10 Apr 2020.
Clinical trials
- Study of Bavituximab in Patients With Advanced Solid Tumor Malignancies
Sponsor: Peregrine Pharmaceuticals
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
36 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Astellas Pharma US IncProgram year20252 payments
- Daiichi Sankyo Inc.Program year20252 payments
- Gilead Sciences, Inc.Program year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
36.5%Phenothiazine28.1%Prochlorperazine Maleate100%Part D≥54 patientsGabapentinoids4.2%Gabapentin100%Part D<11 patients+ 1 more class in this area
Cancer & immunology
20.7%Kinase inhibitor20.7%Imatinib Mesylate59%Tasigna22%Sorafenib19%Part D<11 patientsCardiovascular
17.5%Antiarrhythmic17.5%Lidocaine-Prilocaine100%Part D≥37 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 1998–2012 per NIH RePORTER. The latest:
- Scott & White Community Clinical Oncology Program
Scott and White Memorial Hospital
FY2012$537,993U10CA074647 - Scott & White Community Clinical Oncology Program
Scott and White Memorial Hospital
FY2011$461,207U10CA074647 - Scott & White Community Clinical Oncology Program
Scott and White Memorial Hospital
FY2010$502,117U10CA074647
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Early onset gastric cancer: clinical and molecular insights into a rising epidemic among younger adults
Baylor University Medical Center Proceedings
2025 - The use of cannabinoids in palliating cancer-related symptoms: a narrative review
Baylor University Medical Center Proceedings
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Karen Fink, PhD, MD
Baylor Scott & White Health
Garry Schwartz, MD
Baylor Scott & White Health
Robert Hebeler, MD
Baylor Scott & White Health
Harry Papaconstantinou, MD
Baylor Scott & White Health
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”